潤啤(00291.HK):研究增設人民幣股票交易櫃台
華潤啤酒(00291.HK)表示,留意到香港特區政府近日正積極推動離岸人民幣業務的發展,並計劃推出一系列的舉措,包括鼓勵香港上市公司新增人民幣股票交易櫃台,以「雙幣雙股」模式進行交易。公司認為,有關舉措將提高內地投資者以人民幣參與港股通的意願,有利於增加離岸人民幣市場的流動性,進一步推動人民幣國際化的發展及鞏固香港作為全球離岸人民幣業務領先樞紐的地位。
華潤啤酒認為,通過增設人民幣交易櫃台,公司將有機會增加自港股通及香港離岸人民幣資金池的流動性。公司將密切關注香港特區政府有關政策的發展動向,積極探索新增人民幣股票交易櫃台的可能性,
並考慮在相關方案及機制準備就緒後的適當時候落實推行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.